# Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

> **NCT04505436** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 215 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** HM15211
- **DRUG:** Placebo of HM15211

## Key facts

- **NCT ID:** NCT04505436
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-31
- **Primary completion:** 2026-06-27
- **Final completion:** 2026-07-27
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04505436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04505436, "Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04505436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*